Latest from Incanthera

Initiation of Analyst Research and Release of IGTV Coverage

Initiation of Analyst Research

Release of IGTV Coverage on Commercial Update

Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology is pleased to announce, following its release of a commercial update this morning, that initiation of analyst research by Stanford Capital Partners is now available on the company’s website via the following link:

/investors/research-notes/?document=2024 

Additionally, Incanthera has released a TV interview by Chairman, Tim McCarthy, on the commercial update and analyst research, to its website which can be accessed via the following links:

/news-media/press-coverage/

and

https://bcove.video/3VAhLcu

For further information please contact:

Incanthera plc
www.incanthera.com

Tim McCarthy, Chairman
+44 (0) 7831 675747
tim.mccarthy@incanthera.com

Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
simon.ward@incanthera.com

Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
suzanne.brocks@incanthera.com                                                                     

Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Bob Pountney
+44 (0) 20 3650 3650/51

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

Note to Editors

About Incanthera plc

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.                                                         

For more information on the Company please visit: www.incanthera.com

@incantheraplc 

About Skin + CELL

Skin + CELL is Incanthera’s luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL’s unique formulations, enriched with targeted bioactive B3 (an activated form of niacinamide) are delivered directly into the skin’s cells to optimise and protect cellular health, energy and protective capabilities.

Incanthera’s skincare technology harnesses unique delivery pathways through recently patented formulations designed by our in-house experts who have previously formulated skincare for some of the world’s leading skincare and pharmaceutical companies. These formulations fortify otherwise depleted physiological pathways to improve the skin’s performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

  • Skin + CELL’s unique formulations, currently enriched with targeted bioactive B3 (an activated form of niacinamide) but anticipating further bioactive ingredient formulations are delivered directly into the skin’s cells to optimise cellular health, energy and protective capabilities.
  • Independent studies have shown Incanthera’s technology is uniquely effective in delivering Bioactive B3 below the dermal barrier, energising the living cells of the skin to maintain natural health and protection against adverse environmental challenges and maintaining even skin tones.
  • Skin + CELL’s complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge pharmaceutical enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

Skin + CELL’s luxury skincare current range extends across face, body, hand, face serum and eye serum, and will also include SPF concentrations and further bioactive derivatives of vitamins in the future.

About Marionnaud

Marionnaud is the largest luxury perfumery and cosmetics chain in Europe with over 1,220 stores and a 27% market share in France.  Marionnaud is managed by the AS Watson Group based in Hong Kong, the world’s largest international health and beauty retailer.

https://www.marionnaud.com

About A.S. Watson

The A.S. Watson Group is the world's largest international health and beauty retailer, with 16,100 stores in 28 markets, primarily in Asia and Europe. A member of CK Hutchison Holdings, A.S. Watson operates the world's largest portfolio of retail formats, retail brands and has the largest geographical presence including a significant online retail presence.

http://www.aswatson.com/

https://youtu.be/IZ6TolZi4Go 

Forward looking statement disclaimer

Certain statements made in this announcement, or links contained therein, are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholder holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.